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Abstract
Background: Fatigue is a common symptom in stroke survivors for which there is currently no proven therapy.
Modafinil is a wakefulness-promoting agent with established benefits in other disease models. We aim to test if
modafinil will improve patient’s self-reported fatigue scores when compared to placebo and if therapy results in
increased quality of life.
Methods/design: MIDAS is a phase II, single-centre, prospective, double-blinded, randomised, crossover trial of
modafinil for the treatment of persistent fatigue in survivors of ischaemic stroke. The inclusion criteria will require
an average score of 12 or more across all domains of the Multi-dimensional Fatigue Inventory (MFI-20) and the
diagnosis of a stroke more than 6 months prior. Patients will be randomised 1:1 to receive either modafinil 200 mg
daily or placebo for a period of 6 weeks, after which a crossover will occur where patients who are on modafinil
will begin taking placebo and vice versa. The primary outcome will be improvement in fatigue as measured by the
MFI-20. Secondary outcomes will include changes in the Fatigue Severity Scale, improved cognition measured
using the Montreal Cognitive Assessment, improvement in mood as determined by the Depression, Anxiety and
Stress Scale and improvement in each patient’s stroke-specific quality of life score. All participants will also undergo
magnetic resonance imaging (MRI) at baseline, crossover and study conclusion to measure cerebral blood flow on
arterial spin labelling and brain activity on resting state functional MRI. This study will comply with the CONSORT
guidelines. The projected sample size requirement is 36 participants in a crossover trial giving a power of 80 % and
a type-1 error rate of 0.05.
Discussion: MIDAS seeks to enhance the quality of life in stroke survivors by assisting or resolving stroke-associated
fatigue.
Trial registration: ACTRN12615000350527, registered on the 17 April 2015.
Protocol version 3, approved 16 June 2015.
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Background
Severe fatigue is reported in approximately half of all
stroke survivors [1, 2] and can persist for years after the
index event, resulting in a reduction in quality of life.
Fatigue is a common symptom in chronic disease and is
hypothesised to be caused by a combination of organic
brain lesions and psychosocial stress related to lifestyle
adjustment. Fatigue can also be caused by sleep apnoea
[3] and is a pivotal component of depression [4], which
is also common after stroke. Fatigue after stroke has
been identified to be an independent predictor of poor
outcome [5]; whether this is due to the severity of the
stroke itself or to fatigue directly contributing to poor
outcome is not yet understood. However, neuroimaging
studies have found no clear association between charac-
teristics of the brain lesion (e.g. location, pathological
type) and fatigue [6]. Currently there are no proven ther-
apies for post-stroke fatigue. In the present study, we
seek to investigate if 200 mg daily of modafinil can im-
prove post-stroke fatigue and other aspects of quality of
life in a community-dwelling population.
Modafinil is a nonamphetamine wakefulness-promoting
agent with limited side effects that is currently used to treat
excessive sleepiness associated with narcolepsy, shift-work
sleep disorder and obstructive sleep apnoea. Modafinil has
also been used in the treatment of fatigue associated with
Parkinson’s disease, multiple sclerosis, traumatic brain in-
jury and post-polio syndrome [7]. Several case reports ad-
vocating the use of modafinil in stroke patients have been
published [8, 9]. However, a recent study of modafinil treat-
ment immediately after stroke was negative due to reso-
lution of fatigue in both the control and therapy groups
[10]. We hypothesised that treatment with modafinil would
reduce the severity of self-reported fatigue in stroke survi-
vors compared to placebo.
Methods/design
Modafinil In Debilitating fatigue After Stroke (MIDAS) will
be a phase II, single-centre, prospective, double-blinded,
randomised, crossover trial to investigate if modafinil re-
duces the burden of fatigue after ischaemia in patients who
report ongoing severe fatigue (as measured by the Multidi-
mensional Fatigue Inventory (MFI-20)). This study will
apply the Consolidated Standards of Reporting Trials
(CONSORT) and the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) (Additional
file 1: Figure S1) [11] guidelines. The project protocol was
developed by researchers from the University of Newcastle
without external influence. Data management includes
assigning participants unique study identifiers and scanning
participant documents and backup on secured computers
as detailed in the protocol. The projected total sample size
requirement is 36 participants. Ethical approval was granted
by the Hunter New England Human Research Ethics
Committee in accordance with the Helsinki Deceleration
on 9 June 2015, reference 15/04/15/3.02. Because this is a
single-centre study of 36 participants, no Data Safety
Monitoring Board will be required.
Patient population
Patients will be recruited following from the Newcastle,
NSW, Australia community and from stroke clinics at
John Hunter Hospital. Inclusion criteria will be patients
aged over 18 years with a history of stroke at least
6 months previously and an average score of 12 across
each domain of the MFI-20. All participants are required
to provide informed consent.
Inclusion criteria:
 Being 18 years of age or older
 Having suffered a stroke or transient ischaemic
attack (TIA) at least 3 months previous
 Having persistent self-reported fatigue with a
MFI-20 score of 12 or more
 A modified Rankin Score (mRS) of 3 or less
 Able to speak reasonable English, understand
instructions and be able to complete tests and
questionnaires on their own or with minimal
support
 Able to give informed consent
Exclusion criteria:
 Having pre-existing depression, dementia or other
neuropsychiatric disease
 Having other diagnoses with fatigue as a known
symptom, e.g. chronic fatigue syndrome, multiple
sclerosis
 Having stroke induced by trauma, infection or
surgery
 Current or past drug abuse
 Known contraindication to treatment with modafinil
 Known active malignancy, any intracranial tumor,
subdural or epidural hematoma
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 Known contraindications to MRI scanning, e.g.
claustrophobia, cardiac pacemaker or other implants
 Known cause of fatigue (i.e. sleep apnoea)
 Having renal or hepatic impairment
 Use of benzodiazepines or antiepileptic drugs
 Patients on immunosuppression or known
immunodeficiency state, e.g. HIV
Study drug will be discontinued if there are any ad-
verse events due to the drug (i.e. rash).
Therapy
Participants will be randomised 1:1 to modafinil
200 mg per day or placebo. All participants will be
provided with 6 weeks’ worth of study drug after ran-
domisation. After 6 weeks, participants will be asked
to return to the study centre for assessments and to
return study drug bottles to assess compliance. After
the study drug has been returned, participants will
have a 1-week washout period. Once the washout
period has been completed, participants will again be
asked to return to the study centre and crossover will
occur where participants who initially received moda-
finil will be given a placebo or those who were given
placebo will receive modafinil. Lastly, after 6 weeks
on the second round of the study drug, participants
will be asked to return to the study centre for assess-
ments and to return study drug bottles to assess
compliance.
Assessments
Assessments will be carried out at baseline, in the last
week of the first 6-week treatment arm, after a 1-week
washout period and in the last week of the second 6-
week treatment arm (Fig. 1). The assessment at each
time point will include the MFI-20, the Montreal Cogni-
tive Assessment (MoCA), the Fatigue Severity Scale
(FSS), the Depression, Anxiety and Stress Scale (DASS
42) and the Stroke-specific Quality of Life (SSQoL) scale.
All assessments will be carried out by research staff
blinded to treatment. All participants will also complete
magnetic resonance imaging (MRI) sessions at baseline,
crossover and study conclusion to measure cerebral
blood flow on arterial spin labelling (ASL) and brain ac-
tivity on resting state functional MRI (rsfMRI). Drug ad-
herence will be monitored through tablet return for each
patient in each strata (placebo or active drug).
Consent and randomisation
Participant consent will be obtained following screening
with the MFI-20 by an independent researcher who is
not involved with the routine care of the participant.
Participants will be referred to the research team by cli-
nicians who see stroke survivors in clinics. Where ap-
propriate the clinician will introduce the study to
potential participants if the clinician believes that the
potential participant will meet the inclusion criteria and
be willing and able to provide informed consent as well





















Intervention ------ ------- ------- -------
Cross over ------- ------- ------- -------
Assessment
MFI x x x x
FSS x x x x
MoCA x x x x
DASS42 x x x x
SAQoL x x x x
MRI scan x x x
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram for the MIDAS trial. A SPIRIT diagram of the study
procedures. Following enrolment, patients are randomised to either active drug or placebo. Following 6 weeks of therapy and a 1-week washout,
patients are crossed over either to active drug or placebo. All patient assessments are carried out at the start and conclusion of each therapy
round. MRI scans are performed at the start of the study and at the end of each therapy round. DASS 42, Depression, Anxiety and Stress Scale,
FSS, Fatigue Severity Scale, MFI, Multidimensional Fatigue Inventory, MoCA, Montreal Cognitive Assessment, MRI magnetic resonance imaging,
SSQoL, Stroke-associated Quality of Life
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Patients will be randomly allocated to taking either
200 mg modafinil or an identical placebo daily. Treat-
ment allocation will be performed by the local pharmacy
according to a randomisation schedule generated by an
independent statistical support unit (Clinical Research
Design, IT, and Statistical Support, CReDITSS) at the
Hunter Medical Research Institute. Randomisation will
be based on a computer-generated list of random num-
bers with varying block size, linked to a unique treat-
ment number. All study participants and researchers
outside of the pharmacy will be blinded to treatment al-
location. Unblinding will occur in the event of an ad-
verse or serious adverse event and will be performed by
the pharmacy at the request of the study researchers or
clinicians. A serious adverse events related to modafinil
therapy can include developing a rash, or any event
causing study participant withdrawal or hospitalisation
while in the study. An adverse event will be defined as
the occurrence of headache, nausea, anxiety/nervous-
ness, insomnia, and diarrhoea.
Primary outcomes
The primary outcome will be a significant reduction in
the self-reported MFI-20 score during modafinil treat-
ment compared to that participant’s difference during
the placebo period.
Secondary outcomes
Secondary analyses will assess the effect of treatment
with 200 mg modafinil daily to baseline assessments of
cognition (MoCA), mood (DASS 42) and quality of life
(SSQoL). We will also seek a repeated measure of fatigue
with the FSS which is used more widely yet is much less
specific for the source of type of fatigue.
Secondary analysis will also explore the MRI changes
associated with administering 200 mg modafinil daily in
terms of cerebral blood flow on ASL and brain activity
on rsfMRI.
MRI analysis plan
Secondary analysis will be performed on unblinded pa-
tient data to compare with MRI findings. Resting state
functional MRI (rsfMRI) data will be analysed using in-
dependent component analysis to determine whether
there are different network activation patterns on active
drug or placebo. Arterial spin labelling (ASL) will also
be analysed to determine whether there are any changes
in the whole brain cerebral blood flow between when
participants are on active drug or placebo. Lastly, the
SSQoL, MoCA, DASS 42 and MFI-20 will be analysed
in conjunction with rsfMRI data to identify whether a
change in any score is associated with alterations in rest-
ing state network function.
Statistical analysis plan
A linear mixed model will be used to detect a significant
difference between final MFI-20 scores during each
period as the outcome. The value of the baseline MFI-20
score at trial start and after crossover will be used as a
covariate, and a group variable as the exposure of inter-
est in order to correct for changes in baseline MFI-20
scores; an order term will also be included to make sure
that there is no carryover effect, i.e. no difference in ef-
fect if the active drug or placebo is given first.
Secondary outcomes will be assessed using the same
methods as for the MFI analysis but using the MoCA,
DASS42, SSQoL and FSS instead. MRI analysis will be
undertaken using the same methods as for the primary
analysis.
Given that all secondary outcomes are also continu-
ous, the same approach will be used for analysis of these
outcomes.
Sample size
The study was designed to have 80 % power in detecting
a 10 point decrease in self-reported fatigue on the MFI
after 6 weeks of modafinil treatment with a type I error
rate of 0.05 and assuming standard deviation in the pa-
tient population of 14. Using previously reported effects
of modafinil on fatigue for stroke survivors [10], multiple
sclerosis [12] and a Cochrane review [13] a total sample
size of 34 is required for a crossover study. Assuming
modest participant dropout and study drug compliance,
we aim to recruit 36 participants in total. The crossover
design reduces the number of participants required and
the negative effects of missing data given the small num-
ber of dropouts expected [14].
Discussion
MIDAS seeks to enhance the quality of life in stroke sur-
vivors by assisting or resolving stroke-associated fatigue.
There are limited interventions available to stroke survi-
vors with scant strong evidence establishing their effi-
cacy. The proposed crossover trial is an ideal study
design as the patient disability being examined is already
established, meaning that patients can be enrolled for a
longer period of time and the fatigue has not spontan-
eously resolved as has occurred in an earlier time frames
post stroke [10]. Additionally, by setting the strict inclu-
sion criterion of an average MFI-20 score of 12 across
all domains, we are ensuring that patients have estab-
lished severe fatigue and are able to rule out milder
cases, which may not show a significant change in self-
reported scores. Such individual patient selection has
been the bedrock of recent stroke trials and is a key to
effective therapy delivery. Fatigue is a major health con-
cern for stroke survivors; it reduces their quality of life
and limits engagement in rehabilitation activities. An
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effective therapy may have profound implications for
stroke patients’ quality of life.
Trial status
At the time of writing 24 of the proposed 36 patients
have been enrolled.
Additional file
Additional file 1: Figure S1. SPIRIT checklist for the MIDAS trial. SPIRIT
2013 checklist detailing the MIDAS trial-specific information as described
in the protocol. (PDF 642 kb)
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